REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Portfolio Pulse from
Replimune's stock rises as the FDA grants priority review to its Biologics License Application (BLA) for RP1 in combination with Opdivo for advanced melanoma. A decision is expected by July 22, 2025.
January 22, 2025 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Replimune's stock is positively impacted as the FDA grants priority review to its BLA for RP1 in combination with Opdivo for advanced melanoma, indicating potential for accelerated approval.
The FDA's priority review designation suggests a faster review process, which is a positive signal for Replimune's RP1 drug. This increases investor confidence in the potential approval and market success of the drug, leading to a rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100